Bharat Heavy Electricals Ltd (BHEL) has announced its financial results for the quarter and fiscal year ended March 31, 2025, revealing a modest increase in quarterly net profit but a significant surge in full-year earnings. The results, reported on May 16, 2025, show growth in revenue both year-on-year and sequentially for the final quarter of FY25.
For the quarter ended March 2025, BHEL reported a net profit of ₹504.45 crore. This represents a 3% increase compared to the net profit of ₹489.6 crore in the same quarter last year. While the year-on-year growth was contained, the company saw a considerable sequential improvement, with net profit surging 273% from ₹135 crore recorded in the December 2024 quarter.
Revenue from operations for the March 2025 quarter stood at ₹8993 crore. This marks a 9% increase from ₹8260 crore in the corresponding quarter of the previous year. On a quarter-on-quarter basis, revenue also saw robust growth, rising 23.5% from ₹7277 crore in the December quarter.
Looking at the full fiscal year, BHEL demonstrated strong profit recovery. The company's profit for FY25 soared to ₹533.90 crore, a substantial increase from ₹282.22 crore in FY24.
In addition to the results, BHEL's board recommended a final dividend of 50 paise per share for the financial year FY25. This is equivalent to ₹0.50 per share.
Following the announcement of the results, shares of Bharat Heavy Electricals were noted to be up 1.88% on the NSE, trading at ₹250.31. Earlier in the day, shares had surged by 5% ahead of the results.
In summary, BHEL's Q4 FY25 results show a stable year-on-year profit increase alongside healthy revenue growth. The sequential performance indicates a strong closing quarter for the fiscal year, contributing significantly to the notable increase in full-year profit compared to the previous fiscal year. The recommended dividend reflects the company's performance in FY25.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here